RxDoctor Payments Data

Norman Stevens, MD

Cardiovascular Disease · Greenville, SCNPI 1225390701

Payments from drug & device makers

$4,265in general payments, 2019–2025

Across 207 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Amgen$627
  • Novartis$573
  • Philips North America LLC$337
  • Boehringer Ingelheim$314
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$242
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,20599%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,265 in reported general payments places this provider in the 50th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$256,040
Medicare patients
5,181
Services billed
7,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban461$400,813
Repatha SureclickEvolocumab219$177,827
EntrestoSacubitril/Valsartan108$96,066
XareltoRivaroxaban63$70,112
Praluent PenAlirocumab74$56,860
JardianceEmpagliflozin26$33,648
Repatha PushtronexEvolocumab19$12,290
BrilintaTicagrelor23$10,895
Ranolazine ErRanolazine36$5,856
Metoprolol Succinate472$4,753
Dabigatran EtexilateDabigatran Etexilate Mesylate18$3,672
Atorvastatin Calcium349$3,433
Rosuvastatin Calcium252$2,970
ClopidogrelClopidogrel Bisulfate146$1,623
Carvedilol274$1,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$189$400,813461 claims
NovartisEntresto$573$96,066108 claims
Johnson & JohnsonXarelto$50$70,11263 claims
Boehringer IngelheimJardiance$314$33,64826 claims
AstraZenecaBrilinta$93$10,89523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →